PMA supplement
P110019 S125: Xience Skypoint Everolimus Eluting Coronary Stent System
FDA PMA supplement · Normal 180 Day Track No User Fee · Abbott Vascular
Key facts
| Original PMA | P110019 |
|---|---|
| Supplement number | S125 |
| Supplement type | Normal 180 Day Track No User Fee |
| Reason for the supplement | Postapproval Study Protocol |
| Trade name | Xience Skypoint Everolimus Eluting Coronary Stent System |
| Generic name | Coronary drug-eluting stent |
| Applicant | Abbott Vascular |
| Product code | NIQ |
| Received date | Apr 26, 2023 |
| Decision date | Jul 20, 2023 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: